YBX1 and breast carcinoma: YBX1 acts as a reader to promote oestrogen resistance in progressive breast cancer cells, and can be inhibited by YBX1 phosphorylation inhibitor TAS0612 (a multi‐kinase inhibitor) and everolimus (a rapamycin complex 1 inhibitor).51